Navigation Links
Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
Date:3/13/2008

certain surgical infections. The most common adverse effects may include mild nausea, diarrhea, oral candidiasis and pain or tenderness at the injection site. Less common adverse effects include vomiting, and rarely, pseudomembranous colitis.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... DUBLIN, August 3, 2010 , - Proposed recommended cash acquisition ... a fully diluted equity purchase price of, EUR428 ... date, Movetis held EUR100 million in cash; based on this ... be EUR328 million, - Strong strategic fit with Shire,s growing ...
... ,, ROCKVILLE, Md. , Aug. 2 Vanda Pharmaceuticals Inc. ... the development and commercialization of products for central nervous system disorders, today announced ... August 5, 2010 , before the market opens. A full text copy of ... , , ...
... , CHICAGO and HOBOKEN, N.J. , Aug. 2 ... of the Octapharma 25th Anniversary Grants Program is the Rush ... Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies ... , , ...
Cached Biology Technology:Shire Proposes to Expand Specialist Gastrointestinal Portfolio 2Shire Proposes to Expand Specialist Gastrointestinal Portfolio 3Shire Proposes to Expand Specialist Gastrointestinal Portfolio 4Shire Proposes to Expand Specialist Gastrointestinal Portfolio 5Shire Proposes to Expand Specialist Gastrointestinal Portfolio 6Shire Proposes to Expand Specialist Gastrointestinal Portfolio 7Shire Proposes to Expand Specialist Gastrointestinal Portfolio 8Shire Proposes to Expand Specialist Gastrointestinal Portfolio 9Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
(Date:7/11/2014)... of Chicago is creating a new professorship in ... University,s Institute for Molecular Engineering and the Marine ... from the Millicent and Eugene Bell Foundation., The ... within the Institute for Molecular Engineering. That endowed ... at the MBL,s Eugene Bell Center for Regenerative ...
(Date:7/11/2014)... have set a "mouse TRAP" to capture the early ... study published in the Journal of Clinical Investigation ... called TRAP to extract cellular and genetic information from ... at the Rockefeller Institute for Medical Research in 2008, ... machinery, or ribosomes, of the cell type of interest. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2
... HONOLULU While the iconic Haleakalā silversword plant made a ... a period of substantial climate-related decline. New research published this ... the silversword in its native habitat. Known for its ... single reproductive event at the end of its life, at ...
... structural similarity to asbestos, have been alleviated following research ... In a new study, published today in ... that the asbestos-like reactivity and pathogenicity reported for long, ... is modified and their effective length is reduced as ...
... DENVER Recent studies have demonstrated that molecular-targeted agents, ... inhibitors (TKI), may prolong survival of selected patients based ... EGFR gene is known as a predictive marker for ... EGFR mutations are prognostic factors for non-small cell lung ...
Cached Biology News:Global warming may have severe consequences for rare Haleakalā silverswords 2Chemistry resolves toxic concerns about carbon nanotubes 2EGFR mutation not prognostic factor in non-small cell lung cancer 2
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
... Thermo Electron's most advanced personal gradient option ... use sophisticated onboard software and a large ... offer performance, accuracy and simplicity in thermal ... customer driven features built up on years ...
For testing the AQUA technique on your MS instruments....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
Biology Products: